This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

MiMedx Group, Inc. Sued By Investor

SAN DIEGO and KENNESAW, Ga., Sept. 9, 2013 /PRNewswire/ --  Shareholder rights attorneys at Robbins Arroyo LLP announce that an investor of MiMedx Group, Inc. (NASDAQ: MDXG) has filed a complaint in the U.S. District Court for the Southern District of New York.  The complaint alleges that the company and certain of its officers violated the Securities Exchange Act of 1934 from March 15, 2013 to September 4, 2013 (the "Class Period").  MiMedx, together with its subsidiaries, operates as an integrated developer, manufacturer, and marketer of patent protected regenerative biomaterial products and allografts processed from human amniotic membranes.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36754LOGO)

MiMedx Accused of Making False and Misleading Statements

According to the complaint, MiMedx issued materially false and misleading statements about whether its AmnioFix Injectable product required U.S. Food and Drug Administration ("FDA") approval to be manufactured and marketed.  Specifically, on March 15, 2013, in its annual report for the fiscal year ended December 31, 2013, filed with the U.S. Securities and Exchange Commission ("SEC"), MiMedx falsely stated that its products did not require approval from the FDA because of a purported exemption under the Public Health Service Act.  The company made similar statements in its quarterly report for the second quarter ended June 30, 2013, filed with the SEC on August 8, 2013. 



MiMedx Stock Drops on Announcement of Letter from the FDA Asserting Violations of the Public Heath Service Act

On September 4, 2013, MiMedx confirmed it had received a letter from the FDA stating that the company violated the Public Health Service Act by unlawfully manufacturing drugs and marketing unapproved biologics products without a proper and valid license.  The lawsuit asserts that this adverse information caused the price of MiMedx stock to fall as much as 70%, thereby damaging investors.  

If you invested in MiMedx and would like to discuss your shareholder rights, please contact attorney Darnell R. Donahue at (800) 350-6003, ddonahue@robbinsarroyo.com, or via the shareholder information form on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in securities litigation and shareholder rights law.  The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.  For more information, please go to http://www.robbinsarroyo.com.

Press release link: http://www.robbinsarroyo.com/shareholders-rights-blog/mimedx-group-inc/

Attorney Advertising. Past results do not guarantee a similar outcome.  

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,493.37 -69.93 -0.42%
S&P 500 1,925.15 -5.52 -0.29%
NASDAQ 4,352.6390 -17.1340 -0.39%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs